Article
Higher-order aberrations decreased in most patients, with the change from baseline reaching up to 50%.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
First patient dosed in Qlaris Bio's phase 2 Nightingale clinical trial for QLS-111
3 Things You Should Know About Interventional Glaucoma Comanagement
Post-LASIK presbyopia: Meeting expectations with evolving technology
Patient-Centered Treatment Strategies in the Management of nAMD and DME
Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair
Kriya Therapeutics raises $313.3 funding